Gabriel Robbie
Overview
Explore the profile of Gabriel Robbie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
528
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McDougall R, Ramsden D, Agarwal S, Agarwal S, Aluri K, Arciprete M, et al.
Drug Metab Dispos
. 2021 Jun;
50(6):781-797.
PMID: 34154993
Conjugation of oligonucleotide therapeutics, including small interfering RNAs (siRNAs) or antisense oligonucleotides, to -acetylgalactosamine (GalNAc) ligands has become the primary strategy for hepatocyte-targeted delivery, and with the recent approvals of...
2.
Rocca C, Dennin S, Gu Y, Kim J, Chigas S, Najarian D, et al.
Bioanalysis
. 2019 Dec;
11(21):1927-1939.
PMID: 31829053
The electrophoretic mobility shift assay (EMSA) was evaluated as an alternative to ultrafiltration (UF) to assess plasma protein binding (PPB) of small interfering RNAs (siRNA) and antisense oligonucleotides (ASO). EMSA...
3.
Petri M, Wallace D, Spindler A, Chindalore V, Kalunian K, Mysler E, et al.
Arthritis Rheum
. 2013 Feb;
65(4):1011-21.
PMID: 23400715
Objective: To evaluate the safety and tolerability of multiple intravenous (IV) doses of sifalimumab in adults with moderate-to-severe systemic lupus erythematosus (SLE). Methods: In this multicenter, double-blind, placebo-controlled, sequential dose-escalation...
4.
Annunziata C, Kohn E, LoRusso P, Houston N, Coleman R, Buzoianu M, et al.
Invest New Drugs
. 2012 Feb;
31(1):77-84.
PMID: 22370972
Background: Targeting the cell-surface receptor EphA2, which is highly expressed in some solid tumors, is a novel approach for cancer therapy. We aimed to evaluate the safety profile, maximum tolerated...
5.
Merrill J, Wallace D, Petri M, Kirou K, Yao Y, White W, et al.
Ann Rheum Dis
. 2011 Jul;
70(11):1905-13.
PMID: 21798883
Background: Type I interferons (IFNs) appear to play a central role in disease pathogenesis in systemic lupus erythematosus (SLE), making them potential therapeutic targets. Methods: Safety profile, pharmacokinetics, immunogenicity, pharmacodynamics...
6.
Bissonnette R, Papp K, Maari C, Yao Y, Robbie G, White W, et al.
J Am Acad Dermatol
. 2010 Feb;
62(3):427-36.
PMID: 20159310
Background: Interferon-alfa (IFN-alpha) has been implicated in the pathogenesis of psoriasis. Objective: To evaluate the safety profile of MEDI-545, a fully human anti-IFN-alpha monoclonal antibody and to explore its effect...
7.
White B, Leon F, White W, Robbie G
Clin Ther
. 2009 May;
31(4):728-40.
PMID: 19446146
Background: Interleukin-9 (IL-9) is involved in pathogenic aspects of the asthmatic response, including induction of the proliferation of T-helper type 2 lymphocytes, mucus production, and mast-cell differentiation, proliferation, and recruitment...
8.
Jackson A, Robbie G, Marroum P
Clin Pharmacokinet
. 2004 Jul;
43(10):655-72.
PMID: 15244496
Although it is widely recognised that measurement of metabolite concentrations is crucial to understanding the clinical pharmacology characteristics of a new molecular entity, a clear consensus on the role of...
9.
Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, et al.
Clin Cancer Res
. 2002 Oct;
8(10):3034-8.
PMID: 12374669
Purpose: Imatinib mesylate (Gleevec; Novartis, East Hanover, NJ)is a receptor tyrosine kinase inhibitor approved previously in 2001 by the United States Food and Drug Administration for the treatment of chronic...